Navigation Links
K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus
Date:6/17/2011

ST. LOUIS, June 17, 2011 /PRNewswire/ -- K-V Pharmaceutical Company (NYSE:  KVa/KVb) announced today that it has entered into a definitive agreement to divest Nesher Pharmaceuticals, Inc., its generics subsidiary, and the Company's generic business and assets to Zydus Pharmaceuticals (USA), Inc. for approximately $60 million in cash. The transaction is estimated to close during the second quarter of KV's 2012 fiscal year, subject to customary closing conditions.

The divesture of the Company's generic business has been an important goal of KV's Board of Directors and Management team.  The completion of this divestiture is an important element of the Company's declared strategy of transitioning to a branded specialty pharmaceutical company focused on women's health.  

Jefferies & Company, Inc. acted as exclusive financial advisor to K-V in this transaction.

About K-V Pharmaceutical Company

K-V Pharmaceutical Company is a specialty branded pharmaceutical company with a primary focus in the area of women's healthcare.   As such, we are committed to advancing the health of women across all the stages of their lives.

For further information about K-V Pharmaceutical Company, please visit the Company's corporate Website at www.kvpharmaceutical.com.

Cautionary Note Regarding Forward-looking Statements

This press release contains various forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 (the "PSLRA") and that may be based on or include assumptions concerning the operations, future results and prospects of the Company. Such statements may be identified by the use of words like "plan," "expect," "aim," "believe," "project," "anticipate," "commit," "intend," "estimate," "will," "should," "could," "potential" and other expressions that indicate future events and trends.
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Par Pharmaceutical Reports Second Quarter 2008 Results
3. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
4. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
5. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
6. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
7. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
8. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
9. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
10. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
11. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... ... She has accepted the position of vice president of instruction at Chippewa Valley ... , “I greatly appreciated the opportunity to lead SIUE during the past three ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... Under the terms of the agreement, MediVet will acquire the rights to a ... MB-007 is currently in pre-clinical development as a potential next-generation treatment for various ...
(Date:6/29/2015)...  Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company ... and cell therapy treatments for central nervous system diseases, ... on the NASDAQ Capital Market under the symbol "CUR." ... the NYSE MKT until the market close on July ... expected to commence on July 13, 2015. ...
(Date:6/29/2015)... Elsevier , a world-leading ... services, today announced the highlights of its journal Impact ... Citation Reports® (JCR) published by Thomson Reuters, Elsevier saw ... to 2014, ahead of the aggregate across other journals. ... 62 subject categories, up from 61 in 2013. ...
Breaking Biology Technology:SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3
... Multiporator / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.521 02/2002 , , , ... , Microorganism , ... Cell type , Bacteria, gram positive, , ...
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.514 04/2002 , ... , , , , ... , Cell type , Bacteria, ...
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.511 04/2002 , ... , , , , ... , Cell type , Bacteria, gram ...
Cached Biology Technology:Mycobacterium intracellulare 2Escherichia coli K12 2Escherichia coli K12 3Escherichia coli C600 2Escherichia coli C600 3
(Date:6/30/2015)... , June 30, 2015 To bolster its efforts ... HYPR Corp. announced today the addition of two new team ... as board advisor and David Raviv will act ... underscore HYPR Corp.,s commitment to providing the most secure solutions ... Sirota co-founded Layer 7 Technologies, a provider of security ...
(Date:6/30/2015)... Pa. , June 30, 2015 ... the company as CEO to help further develop Genisphere,s ... wealth of partnering experience, having spent much of the ... including Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. ... focus on Technology and Biotech Corporate Finance. He graduated ...
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... ARBOR, Mich. An early laboratory success is taking ... gland transplants that could one day prevent a currently ... The scientists were able to induce embryonic stem ... hormone essential to maintaining bone density. The laboratory results ...
... ANN ARBOR, Mich.---Brain implants that can more clearly record ... at the University of Michigan. The findings could eventually ... as Parkinson,s disease and paralysis. Neural electrodes must ... When the electrodes are implanted, the brain first reacts ...
... calling on Congress to support the Consistency, Accuracy, Responsibility ... (CARE bill), which would ensure that states set minimum ... bill (H.R. 3652) was introduced Sept. 28 in the ... "The introduction of the CARE bill ...
Cached Biology News:Stem cell success points to way to regenerate parathyroid glands 2A step toward better brain implants using conducting polymer nanotubes 2A step toward better brain implants using conducting polymer nanotubes 3SNM urges Congress to support CARE bill 2
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
...
Mouse polyclonal antibody to NR2F2 - nuclear receptor subfamily 2, group F, member 2...
... Pack provides optimized blocking and wash ... Clarifier: Ready-to-use wash solutions have been ... Coated Slides for Microarrays (Product Code ... Buffer: 1L • Microarray Post Hybridization ...
Biology Products: